Early-stage Immune System Control Of HIV May Depend On Inherited Factors

|

HIV researchHow well an individual's immune system controls HIV during the earliest phases of infection appears to depend on both the specific versions of key immune-system molecules called HLA Class I that have been inherited, as well as on the fragments of viral protein those molecules display to the T lymphocytes that usually destroy infected cells.

In a report in the November issue of PLOS Medicine, researchers from the Partners AIDS Research Center at Massachusetts General Hospital (PARC/MGH) report that specific HLA Class I/HIV viral fragment combinations are associated with a more powerful antiviral response, findings that may help develop vaccines against HIV.

"We found that only a limited number of viral protein fragments from HIV-1 are targeted by the immune system in early infection and that the versions of HLA Class I previously associated with slower HIV-1 disease progression also contribute more to this initial antiviral immune response," says Marcus Altfeld, MD, PhD, of PARC/MGH, the paper's lead author. 

HLA -- also called major histocompatibility complex (MHC) -- proteins are also the primary markers of tissues as "self." Unique to each individual, these are the factors that need to be matched as closely as possible in organ transplants, with perfect matches only possible between identical twins. Some studies have found that HIV patients with particular versions of HLA may be better able to control viral levels, but the diversity of HLA molecules -- each person may have up to six different varieties of Class I proteins -- has made investigating the role of HLA type in HIV infection challenging.

The current study was designed to determine the contribution of both HLA Class I and the particular viral fragments displayed on those molecules to the activation of HIV-specific CD8 cells. The researchers analyzed blood samples from more than 100 people recently infected with HIV, first determining their specific HLA types by DNA analysis. Then they focused on 173 HIV protein fragments known to bind to those HLA types to see if particular peptides were more powerful in activating the HIV-specific CD8 response.

The researchers found that, for many varieties of HLA, only a few HIV protein fragments were responsible for the activation of CD8 T cells early in infection. In addition, the same HLA types that had been previously identified in people who stay healthy for a longer period of time after initial infection were associated with a more powerful early-stage HIV-specific CD8 activity.

"While we can't say this for sure right now, it is looking like both the HLA Class I molecule and the specific viral sequences being displayed contribute to the strength of immune response against primary HIV infection," says Altfeld. "In addition, the combination of Class I molecules that an individual expresses, something that is genetically determined, seems to have a significant impact on the specificity and strength of that response.

"Identifying the HIV epitopes [viral fragments] that are particularly good at priming an early T cell response may be important to vaccine design, and the impact of an individual's genetic HLA Class I background implies that a successful vaccine would have to overcome genetic factors associated with a less protective response," he adds. Altfeld is an associate professor of Medicine at Harvard Medical School. He and his colleagues are working on a follow-up study with samples from 500 individuals to further investigate the impact of HLA Class I on the control of HIV replication.

The study was supported by grants from the National Institutes of Health and the Doris Duke Charitable Foundation, with additional support from the National Cancer Institute and the Center for Cancer Research. In addition to senior author Bruce Walker, MD, director of the Partners AIDS Research Center at Massachusetts General Hospital, the report's co-authors are Elizabeth Kalife, Hendrik Streeck, MD, Mathias Lichterfeld, MD, Mary Johnston, Nicole Burgett, Martha Swartz, Amy Yang, Galit Alter, PhD, Xu Yu, MD, Angela Meier, MD, Todd Allen, PhD, and Eric Rosenberg, MD, of PARC/MGH; Ying Qi and Mary Carrington, PhD, of the National Cancer Institute, Heiko Jessen, MD, Gemeinschaftspraxis Jessen, Berlin; and Juergen Rockstroh, MD, PhD, University of Bonn, Germany.

source 

About this Entry

This page contains a single entry by ID Admin published on November 4, 2006 9:35 PM.

HIV test price cut to half was the previous entry in this blog.

Global health fund fails to select new director is the next entry in this blog.

Find recent content on the main index or look in the archives to find all content.

Pages

Powered by Movable Type 4.24-en